Hematology Analyzers Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Hematology Analyzers market is Segmented by Product (Instruments, Reagents, and Services), End Users (Hospitals, Clinical Laboratories, Research Institutes, and Others), and Geography (North America, Europe, Asia Pacific, Middle-East and Africa, and South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

hematology analyzers market
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 7.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The hematology analyzers market is projected to register a CAGR of 7.6% during the forecast period (2022-2027). 

There was an increasing focus on the hematology parameters for the assessment of COVID-19 around the world. Several studies are carried out in research institutions, and many hospitals started using hematology analyzers to test and monitor COVID-19 patients without spreading the virus. For the practical and efficient screening of large populations for the COVID-19 infection, some research studies from China recommended including white blood cells (WBC) and C-reactive protein (CRP) in laboratory examinations for early monitoring of infection. On March 18, 2020, Sight announced that Israel’s government-run Sheba Tel Hashomer Hospital is using its OLO, the first blood count device for point-of-care to conduct CBC tests to monitor and treat its COVID-19 patients to mitigate the risk of contamination.

Additionally, the review published in Physiological Review-Journal suggests that high levels of an enzyme involved in blood clot prevention may be a common risk factor for developing COVID-19. Furthermore, the correct treatment and management of infection by Coronavirus (COVID-19) in patients affected by hematological disorders may be challenging given the rapid spread of the pandemic and limited literature so far.

Moreover, the major factors for the growth of the hematology analyzers market include the rising burden of blood disorders, increasing technological advancements, and rising adoption rates of automated hematology instruments.

Blood disorders have become a global health issue with different causes and are associated with high mortality. Blood disorders, such as anemia, blood cancers, hemorrhagic conditions, and infections in the blood, affect millions of people each year across all age groups. According to the Australian Government, Department of Health and Aged Care report in 2022, more than 330,000 affected infants are born each year (83% sickle cell disorders and 17% thalassaemias), around 7% of pregnant women are carriers of hemoglobin disorders, and over 1% of couples are at risk at a global level. As per the World Federation of Hemophilia, in 2020, the prevalence of among men hemophilia was found to be around 17 per 100,000 males, globally.

Similarly, according to the World Federation of Hemophilia report updated July 2022, more than 1,125,000 men worldwide have an inherited bleeding disorder, and 418,000 of those have a severe version of the most undiagnosed disease. Early diagnosis and treatment are the best ways to protect the quality of life of a patient with a blood cell disorder. Hence, the increasing burden of blood disorders is likely to drive the market in the future.

However, the high cost of hematology analyzers and time-consuming and stringent regulatory policies associated with the same is restraining the overall market growth.

Scope of the Report

As per the scope of this report, hematology analyzers are the equipment used to run tests on blood samples, and they are used in the medical field to determine white blood cell counts, complete blood counts, reticulocyte analysis, and coagulation tests. The Hematology Analyzers market is Segmented by Product (Instruments, Reagents, and Services), End Users (Hospitals, Clinical Laboratories, Research Institutes, and Others), and Geography (North America, Europe, Asia Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Product Type
3 Part Hematology Analyzer
5 Part Hematology Analyzer
Point-of-care Testing Hematology Analyzers
By End User
Clinical Laboratories
Research Institutes
Other End Users
North America
United States
United Kingdom
Rest of Europe
South Korea
Rest of Asia-Pacific
Middle East and Africa
South Africa
Rest of Middle East and Africa
South America
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

3 Part Hematology Analyzer is the Segment by Instruments Expected to Hold Largest Market Share

A 3-part differential cell counter uses Coulter's Principle to find the size and volume of the cell. The sample is lysed and dissolved into an electrolyte solution in a container, which also holds a smaller container. 3-part hematology analyzer systems are ideally suited for physician office laboratories, clinics, and small hospitals that perform moderately complex testing. There is increased interest in 5-part hematology analyzers, however, 3-part hematology analyzers are more cost-effective for routine hematological tests. Furthermore, with advancements in technology and availability of these instruments across the world coupled with affordability the market is projected to have notable growth.

In March 2019, Transasia Bio-Medicals Ltd has launched the 3-Part Differential (3PD) fully automated hematology analyzers, reagents, and controls in India that were manufactured by Erba Lachema a fully owned European subsidiary of Transasia. Later in September 2019, Transasia Bio-Medicals Ltd. announced that it has successfully sold over 1,000 units of its Erba Hematology range of analyzers in India.

In April 2019, Prestige Diagnostics has launched its NEW Hematron 3 PLUS Hematology Analyzer, globally. It is a 3-part differential hematology analyzer capable of performing 18 parameters with 3 histograms.

. Furthermore, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.

Hematology Analyzer

North America is Expected to Dominate the Studied Market

The market for hematology analyzers in the North American region is growing at a steady pace. This can be attributed to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the diagnostic industry. For instance, anemia, which is a common disorder, affects more than three million Americans, particularly women of ‘childbearing age.

According to the Center for Disease Control and Prevention(CDC) report in 2020, Hemophilia A affects 1 in 5000 male births. About 400 babies were born with hemophilia A each year. According to the Leukemia and Lymphoma Society in 2021, every three minutes, a person in the United States is diagnosed with blood cancer. An estimated 186,400 people in the United States were diagnosed with leukemia, lymphoma, or melanoma in 2021.

Many market players are present in the country and are continuously focusing on the development and introduction of novel products. In February 2021 Beckman Coulter launched the DxH 560 AL, a tabletop hematology analyzer designed to reduce time and resource constraints face by small- to mid sized laboratories.

Moreover, in the United States, there are a number of associations helping both clinicians and scientists across the world who are working to conquer such blood diseases. Furthermore, many centers in the state are international leaders in the diagnosis and treatment of blood diseases and collaborate in many research projects to improve diagnosis and treatment options for blood diseases. These factors drive the demand for hematology analyzers in the North American region.

Hematology Analyzers Market - Growth Rate by Region

Competitive Landscape

The market studied is a fragmented market owing to the presence of various market players. Some of the market players are Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories, Boule Diagnostics AB, F Hoffmann-La Roche Ltd, Hobira Ltd, Nihon Kohden Corporation, Mindray Medical International Limited (Shenzhen Mindray Bio-Medical Electronics Co. Ltd), Siemens Healthineers, and Sysmex Corporation.

Recent Developments

  • In April 2022 Sysmex Europe Launched its new three-part differential automated hematology analyzer, XQ-320. It is a robust device with low demands for sample volume, bench space, and maintenance in Europe
  • In February 2021, the company Beckman Coulter announced the launch of DxH 560 AL, a tabletop hematology analyzer in United States.

Table of Contents


    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rising Burden of Blood Disorders

      2. 4.2.2 Increasing Technological Advancements

      3. 4.2.3 Rising Adoption Rates of Automated Hematology Instruments

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Hematology Analyzers

      2. 4.3.2 Time-consuming and Stringent Rregulatory Policies

    4. 4.4 Industry Attractiveness - Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Buyers/Consumers

      2. 4.4.2 Bargaining Power of Suppliers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value – USD million)

    1. 5.1 By Product Type

      1. 5.1.1 Instruments

        1. 3 Part Hematology Analyzer

        2. 5 Part Hematology Analyzer

        3. Point-of-care Testing Hematology Analyzers

        4. Others

      2. 5.1.2 Reagents

      3. 5.1.3 Services

    2. 5.2 By End User

      1. 5.2.1 Hospitals

      2. 5.2.2 Clinical Laboratories

      3. 5.2.3 Research Institutes

      4. 5.2.4 Other End Users

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico

      2. 5.3.2 Europe

        1. Germany

        2. United Kingdom

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. China

        2. Japan

        3. India

        4. Australia

        5. South Korea

        6. Rest of Asia-Pacific

      4. 5.3.4 Middle East and Africa

        1. GCC

        2. South Africa

        3. Rest of Middle East and Africa

      5. 5.3.5 South America

        1. Brazil

        2. Argentina

        3. Rest of South America


    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories

      2. 6.1.2 Beckman Coulter Inc. (Danaher Corporation)

      3. 6.1.3 Bio-Rad Laboratories

      4. 6.1.4 Boule Diagnostics AB

      5. 6.1.5 F Hoffmann-La Roche Ltd

      6. 6.1.6 Horiba Ltd

      7. 6.1.7 Nihon Kohden Corporation

      8. 6.1.8 Mindray Medical International Limited (Shenzhen Mindray Bio-Medical Electronics Co, Ltd)

      9. 6.1.9 Siemens Healthineers

      10. 6.1.10 Sysmex Corporation

      11. 6.1.11 Stratec Biomedical Systems (DIATRON)



    2. *List Not Exhaustive

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global Hematology Analyzers Market market is studied from 2019 - 2027.

The Global Hematology Analyzers Market is growing at a CAGR of 7.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Abbott Laboratories, HORIBA Ltd, Siemens Healthineers, Sysmex Corporation, Danaher Corporation are the major companies operating in Global Hematology Analyzers Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!